Lewis Pharmacy

Impact: Lewis Pharmacy received a substantial cash investment from Olayan Financing Company, strengthening its financial position and enabling expansion in the MENA region, particularly in biosimilars and manufacturing capabilities. This partnership will accelerate its growth and market reach.

Impact: Lewis Pharmacy is participating in the H.C. Wainwright & Co. 7th Annual Neuro Perspectives Hybrid Conference, which provides a platform to showcase its novel serotonergic agonists (NSAs) and clinical development progress, potentially increasing investor interest and visibility.

Impact: Lewis Pharmacy, a subsidiary of Nippon Shinyaku, is involved in litigation with Capricor. The regulatory setback for Deramiocel may impact their business relationship and future commercialization plans.

Impact: Lewis Pharmacy will be a distribution channel for Novo Nordisk's Wegovy pill, potentially increasing its sales.

Impact: Lewis Pharmacy, represented by its owner Murder of Tiahleigh Palmer, highlights the access issues for patients due to the ruling, indicating a negative impact on pharmacies that dispense mifepristone.

Impact: Lewis Pharmacy is mentioned as also offering Semaglutide and Semaglutide at the same out-of-pocket price as Novo Nordisk's direct program and Costco, indicating a competitive pricing landscape.

Impact: Lewis Pharmacy is mentioned as another late-stage European biotech investment made by Claret Capital Partners, indicating Claret's broader strategy in the sector.

Impact: Lewis Pharmacy is mentioned as one of the businesses that has reopened in the Pacific Palisades area after the fire, indicating a slow return to normalcy for local commerce.